Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis

Table 2 Details of tested indicators

Indicator	Detail
ASAS	Assessment of spondylo arthritis international society improvement of 40% (ASAS 40): improvement of at least 3 in 4 indices ≥ 40% and improvement score ≥ 2 (total score 10) or ≥ 20 (total score 100) ASAS 20: improvement of at least 3 in 4 indices ≥ 20% and improvement score ≥ 1 (total score 10) or ≥ 10 (total score 100) ASAS PR: improvement of all 4 indices ≤ 20% and improvement score ≤ 2 (total score 10) or ≤ 20 (total score 100)
BASDAI50	Bath ankylosing spondylitis disease activity index improvement of 50%
ASDAS LDA	ASDAS low disease activity [C-reactive protein (CRP) < 2.1 mg/L]
ASDAS ID	ASDAS inactive disease (CRP < 1.32 mg/L)
BASFI	Bath ankylosing spondylitis function index
MASES	Maastricht ankylosing spondylitis enthesitis score
SPARCC MRI	Spondylo arthritis research consortium of Canada magnetic resonance imaging spine
	SPARCC MRI sacroiliac joint
ASDAS CRP	Ankylosing spondylitis disease activity score C-reactive protein
Improvement of quality of life	ASQOL: Ankylosing spondylitis quality of life inventory
Improvement of quality of life	ASAS HI: ASAS health index
SF-36PCS	Physical component summary score of the short form 36

Note ASAS 40, ASAS 20, ASAS PR, BASDAI50, Improvement of quality of life, ASDAS LDA, ASDAS ID, and SF-36PCS refer to numbers of the AS patients in the placebo and UPA groups (15 mg, q.d, 14 w) whom reach criteria of these indices; ASDAS CRP, total back pain, nighttime back pain, SPARCC MRI, BASFI, and MASES refer to difference values of these indices’ scores between the treatment (Placebo or UPA treatment at 14th week) and the baseline (Placebo or UPA treatment at 0 week)

ISSN: 2520-1026